Target intelligence / Profile preview

Protein phosphatase 3 catalytic subunit beta (PPP3CB)

Target
PPP3CB
Molecular classification
Enzyme, Serine/threonine phosphatase, Protein phosphatase, Calmodulin-dependent protein phosphatase
01

Overview

Protein phosphatase 3 catalytic subunit beta (PPP3CB), also known as calcineurin A beta, is a calcium-dependent, calmodulin-stimulated serine/threonine phosphatase that is essential for intracellular Ca²⁺-mediated signal transduction[1][3]. It dephosphorylates and regulates several downstream substrates, including transcription factors such as NFAT and ELK1, influencing gene expression, lysosome biogenesis, and cell signaling. PPP3CB forms the catalytic core of the calcineurin complex, plays roles in the immune response, neural signaling, and muscle physiology, and is implicated in cardiovascular, renal, and neuropsychiatric diseases. It is directly targeted by immunosuppressant drugs such as cyclosporin A and tacrolimus[1][3][7].

Other names
Calcineurin A betaProtein phosphatase 2B catalytic subunit beta isoformCalmodulin-dependent calcineurin A subunit beta isoformCNA betaCalcineurin A2CALNA2CALNBCNA2PP2BbetaProtein phosphatase from PCR fragment H32Serine/threonine-protein phosphatase 2B catalytic subunit beta isoformCAM-PRP catalytic subunitProtein phosphatase 3, catalytic subunit, beta isoform
02

Mechanism of action

Inhibition of calcineurin phosphatase activity (both cyclosporin A and tacrolimus act by forming complexes with immunophilins, which then inhibit calcineurin, suppressing dephosphorylation and activation of NFAT transcription factors)

03

Biological functions

Signal transductionCalcium-dependent intracellular signalingDephosphorylation of proteinsRegulation of lysosome organizationRegulation of transcription factor activity (NFAT, ELK1)Regulation of lysosomal biogenesisSkeletal muscle fiber type specification
04

Disease associations

Cardiovascular disease (aortic valve stenosis)Neuropsychiatric disorders (schizophrenia)Renal disease (focal segmental glomerulosclerosis)Neurodegenerative diseaseOther (spastic paraplegia, optic atrophy, and neuropathy)
05

Safety considerations

Immunosuppression (increased risk of infection with calcineurin inhibitors)NephrotoxicityNeurotoxicity
06

Interacting drugs

Cyclosporin A

1 more in the full profile.

07

Biomarkers

Potential biomarker for focal segmental glomerulosclerosisPotential biomarker for schizophrenia

Beyond the preview

Go deeper on Protein phosphatase 3 catalytic subunit beta (PPP3CB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein phosphatase 3 catalytic subunit beta (PPP3CB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call